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Using Vero cells, we isolated a virus (NII561-2000) 
from a cerebrospinal ﬂ  uid specimen of a 1-year-old girl with 
Reye syndrome. The determined amino acid sequence of 
the virus indicated that the isolate was a human parechovi-
rus (HPeV), a member of Picornaviridae. Neutralization test 
showed that the NII561-2000 virus had distinct antigenicity 
to HPeV-1, HPeV-2, and HPeV-3, and that the sequence 
was distinct from these types as well as from HPeV-4 and 
HPeV-5. Thus, we propose the virus (NII561-2000) as the 
prototype of HPeV-6. We isolated 10 NII561-2000–related 
viruses, 14 HPeV-1, 16 HPeV-3, and 1 HPeV-4 of 41 HPeVs 
from various clinical samples collected in Niigata, Japan. 
Clinical symptoms of the persons infected with the NII561-
2000–related viruses were infectious gastroenteritis, rash, 
upper respiratory tract infection, and paralysis, in addition to 
Reye syndrome in the 1-year-old girl.
H
uman parechovirus (HPeV) is a small, nonenveloped 
RNA virus with a single-stranded genome of posi-
tive polarity, ≈7.3 kb in length; it is a member of the Pi-
cornaviridae family (1–3). On the basis of serologic and 
genetic studies, HPeV has been found to have 5 types, 
HPeV-1, HPeV-2, HPeV-3, HPeV-4, and HPeV-5, with 
76.0%–80.9% similarity at the nucleotide level and 84.7%–
90.0% similarity at the amino acid level (1,4–7). HPeV in-
fections are commonly observed in general populations. 
For example, ≈20% of healthy children in Finland have 
antibodies against HPeV-1, and the percentage is as high as 
97% in adults (8). In addition, these viruses are frequently 
isolated from patients with various human diseases, such as 
gastroenteritis, encephalitis, ﬂ  accid paralysis, and respira-
tory infections, and they are thought to be associated with 
these diseases (2,3,5,8,9).
We report a 1-year-old girl who died with Reye syn-
drome, which is characterized as an acute, noninﬂ  amma-
tory encephalopathy with hepatic dysfunction and fatty 
inﬁ  ltration of the viscera; the syndrome is frequently asso-
ciated with an antecedent viral infection, such as inﬂ  uenza 
or varicella (10–12). Inoculation of a cerebrospinal ﬂ  uid 
(CSF) specimen from the patient into Vero cells identiﬁ  ed a 
virus (NII561-2000) with similar properties to HPeVs. The 
nucleotide sequence of this virus showed it was closely re-
lated to HPeVs, especially HPeV-1, with 79.5% nucleotide 
and 90.7% amino acid (aa) similarities. Moreover, mutual 
neutralization assay showed that NII561-2000 has distinct 
antigenicity to HPeV-1, HPeV-2, and HPeV-3. In addition, 
the NII561-2000 virus was genetically distinct from HPeV-
4 and HPeV-5. Thus, we propose that NII561-2000 is the 
prototype of HPeV-6.
Materials and Methods
Cell Lines and Culture Conditions
Eight adherent cell lines, MDCK, Caco-2, RD-18S, 
Vero, HeLa, HEp-2, LLC-MK2, and BSC-1, were used in 
our study. In brief, MDCK originated from a kidney of a 
normal adult cocker spaniel, Caco-2 was from a primary 
colorectal adenocarcinoma, RD-18S was from a rhabdo-
myosarcoma, Vero was from the kidney of a normal adult 
African green monkey, HeLa was from a cervical adeno-
carcinoma, HEp-2 was from an epidermoid carcinoma of 
the larynx, LLC-MK2 was from a kidney of a normal adult 
rhesus monkey, and BSC-1 was from a kidney of a normal 
adult African green monkey. These cell lines were cultured 
in Eagle minimum essential medium with 6 mmol/L L-glu-
tamine, 1.1 g/L sodium bicarbonate, antimicrobial agents 
(0.2 g/L gentamicin, 0.25 g/L amphotericin B), and 8% fe-
tal bovine serum at 37°C under 5% carbon dioxide.
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Virus Isolation and Puriﬁ  cation
MDCK, Caco-2, RD-18S, Vero, HeLa, HEp-2, LLC-
MK2, and BSC-1 cells were cultured on 24-well plates 
for 3 days. Then, these cells were inoculated with a CSF 
specimen (100 μL per well) from a patient with a diagnosis 
of Reye syndrome and cultured at 33°C for 2 weeks. To 
check for cytopathic effect (CPE), we examined the cells 
under a light microscope. To purify the virus particles, we 
mixed 900 mL culture ﬂ  uid of Vero cells inoculated with 
the NII561-2000 virus with 20 g NaCl and 76 g polyethyl-
ene glycol #6,000 at 4°C overnight. Next, the sample was 
centrifuged at 5,000 rpm for 30 min, and the pellets were 
suspended in 4.5 mL of phosphate buffer (pH 7.2). After 
treatment with 4.5 mL of chloroform at 4°C for 5 min, the 
sample was centrifuged at 2,500 rpm for 20 min. The su-
pernatant was centrifuged at 120,000 × g for 24 h in cesium 
chloride (CsCl) solution at an initial density of 1.34 g/mL, 
and the virion-containing fraction was collected and used 
for viral RNA isolation.
Molecular Cloning
Double-stranded cDNA was synthesized from 5 μg of 
the viral RNA from the viruses puriﬁ  ed by the CsCl density 
gradient ultracentrifugation method described above. The 
nucleotide sequences of the cDNAs from randomly picked-
up bacterial colonies transfected with the cDNA-containing 
plasmids were determined by using the Big Dye sequenc-
ing kit (Applied Biosystems, Foster City, CA, USA). Two       
cDNAs isolated contained part of the NII561-2000 gene. To 
isolate the 3′ cDNA fragment of the isolated NII561-2000 
cDNAs, the 3′ rapid ampliﬁ  cation of cDNA ends (RACE) 
was performed by using the RNA PCR Kit (AMV) accord-
ing to the instructions provided by the supplier (TaKaRa, 
Kyoto, Japan). The primers used for 3′ RACE were 35F-
out (forward primer for the ﬁ  rst PCR; 5′-GAT GCG GAA 
AAC TGC TGG ACA C-3′), 35F-in (forward primer for 
the second PCR; 5′-TGC CAA ATT TTT CTG CCC TAC 
TG-3′), and M13M4 (reverse primer for the ﬁ  rst and sec-
ond PCR; 5′-GTT TTC CCA GTC ACG AC-3′). Hercu-
lase Hotstart DNA Polymerase (Stratagene, La Jolla, CA, 
USA) was used. To isolate the 5′ cDNA fragment of the 
isolated NII561-2000, the cDNA fragment containing part 
of the 5′ untranslated region (UTR) and capsid precursor 
protein VP0 was ampliﬁ  ed by PCR from the cDNA pre-
pared from the NII561-2000 virus with degenerate primers 
corresponding to this region. The degenerate primers used 
were E23P1 (forward primer; 5′-CCG YAG GTA ACA 
AGW GAC AT-3′) (5) and 35R (reverse primer; 5′-TCT 
CAG CAC TAA TGA CCC TC-3′). To further extend the 
sequence information of 5′ UTR of the NII561-2000 vi-
rus, the 5′ RACE was performed with 5′ RACE System for 
Rapid Ampliﬁ  cation of cDNA Ends (Version 2.0), by us-
ing the instructions provided by the supplier (Invitrogen, 
San Diego, CA, USA). The primers used for 5′ RACE were 
AAP (forward primer for the ﬁ  rst PCR; 5′-GGC CAC GCG 
TCG ACT AGT ACG GGI IGG GII GGG IIG-3′) HPeV-
GSP2 (reverse primer for the ﬁ  rst PCR; 5′-AGA TGC ATC 
ATC TGC GAC TC-3′), UAP (forward primer for the sec-
ond PCR; 5′-CUA CUA CUA CUA GGC CAC GCG TCG 
ACT AGT AC-3′), and HPeV-GSP (reverse primer for the 
second PCR; 5′GCC ATG TCT GCA ATG CTC TT-3′). 
Taq polymerase (Biotech International, Bentley, Western 
Australia, Australia) was used as a polymerase. Because 5′ 
RACE did not reach to the 5′ end of the NII561-2000 virus 
cDNA, the 5′ end cDNA fragment of the NII561-2000 vi-
rus was ampliﬁ  ed from the NII561-2000 viral RNA by re-
verse transcription–PCR (RT-PCR). The primers used for 
RT-PCR were HPeV-head (forward primer; 5′-TTT GAA 
AGG GGT CTC CT-3′) and HPeV-mid (reverse primer; 
5′-CAT AAG TTC CAC AAG CGT GG-3′) HPeV-head 
primer was designed as a conserved 5′ end sequence of the 
HPeVs 5′ UTR.
Neutralization Test
Twenty-ﬁ   ve microliters (100 median tissue culture 
doses; 50% tissue infective dose [TCID50]) of the indicated 
viruses and 25 μL of the serially diluted antisera (an ini-
tial 10-fold dilution and then 2-fold serial dilutions) were 
mixed in a 96-well plate and incubated at 37°C for 2 h. 
Then suspended Vero cells (100 μL/well) were added into 
these wells. Three to 10 days later the CPE of Vero cells 
was checked by light microscopy. To prepare the antiserum 
against the NII561-2000 virus, the virus particles grown 
in Vero cells were puriﬁ  ed by CsCl centrifugation as de-
scribed above. By using this puriﬁ  ed virus, we prepared 
antiserum by Nippon Biotest Laboratory (Tokyo, Japan). 
In brief, the puriﬁ  ed viruses were subcutaneously injected 
into rabbits 3× every 2 weeks. After we checked the anti-
viral titer by the Ouchterlony method, blood was collected 
from the vaccinated rabbits.
Comparisons of VP0 Amino Acid Sequences of Clini-
cal Isolates
To determine the VP0 amino acid sequences of viruses 
isolated from clinical samples with cultured cell lines, we 
extracted the viral RNA from culture supernatant of cells 
injected with the clinical samples by using the High Pure 
Viral RNA Kit (Roche, Mannheim, Germany). cDNA 
was synthesized from 8 μL  of  the  viral  RNA  by  using                      
1 U Moloney murine leukemia virus reverse transcriptase 
(Invitrogen) and 20 U of recombinant RNAs in ribonucle-
ase inhibitor (Promega, Madison, WI, USA). The 810-bp 
fragment containing part of 5′ UTR and VP0 was ampliﬁ  ed 
by PCR, using 5 μL of cDNA in a 50-μL reaction mixture 
containing 50 mmol/L KCl, 10 mmol/L Tris/HCl (pH 8.5), 
2.5 mmol/L MgCl2, 0.2 mmol/L of each deoxynucleoside Novel Human Parechovirus
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triphosphates, 50 pmol of each primer, and 1 U of Taq poly-
merase (Biotech International). The ampliﬁ  cation reaction 
consisted of 30 cycles at 95°C for 30 s, at 59°C for 30 s, 
and at 72°C for 1 min. The primer set used was E23P1 as 
a forward primer and HPV-N1 (5′-TAG GGG ATA CAT 
ARG TCR GCY T-3′) as a reverse primer (5).
Phylogenic Tree Analysis
The bootstrap values were calculated from P1 amino 
acid sequences of parechoviruses with the CLUSTAL X 
software program (13), and the phylogenetic tree of these 
P1 amino acid sequences was constructed by using the 
neighbor-joining method. The nucleotide sequences of the 
following parechoviruses were obtained from GenBank: 
and their accession numbers were L02971 for HPeV-1 
(Harris strain), AJ005695 for HPeV-2 (Williamson strain), 
AB084913 for HPeV-3(A308/99), AJ889918 for HPeV-3 
(Can82853-01), DQ315670 for HPeV-4 (K251176-02), 
AM235750 for HPeV-4 (T75-4077), AF055846 for HPeV-
5 (CT86-6760), AM235749 for HPeV-5 (T92-15), and 
AF327920 for Ljungan virus (LV). The GenBank/EMBL/
DDBJ accession numbers of NII428-2000, NII2392-2001, 
NII2667-2001, NII2694-2001, NII2729-2001, and NII561-
2000 are AB252577–AB252582.
Results
Virus Isolation
In January 2000, a 1-year-old girl with croup and high 
fever (39.6°C) was hospitalized in a regional general hos-
pital in Niigata Prefecture, Japan. The infant died, and her 
condition was diagnosed as Reye syndrome after postmor-
tem pathologic examination. To identify the pathogenic 
agent, we added a CSF specimen collected before death to 
8 cell lines: MDCK, Caco-2, RD-18S, Vero, HeLa, HEp-2, 
LLC-MK2, and BSC-1 cells. Only Vero cells inoculated 
with the specimen exhibited a CPE. The CPE titer of the 
culture ﬂ  uid was 105–106 TCID50 per 25 μL against Vero 
cells. Electron microscopic examination detected typical 
enteroviruslike virions in the culture ﬂ  uid of the specimen 
(round, no envelop, ≈30 nm in diameter). Taken together, 
these results suggested that the CSF from the patient con-
tained a virus, which we refer to here as NII561-2000.
Physical and Antigenic Properties
Neutralization tests were performed to examine 
whether the NII561-2000 agent is related to known vi-
ruses. The NII561-2000 virus infection of Vero cells was 
not neutralized by a pool of enterovirus typing antisera or 
3 HPeV typing antisera [(HPeV-1, HPeV-2, and HPeV-3) 
(A308/99)] (Table 1). Conversely, the rabbit antiserum to 
the NII561-2000 virus did not neutralize the infection of 
prototype strains of echovirus (serotypes 1–6, 9, 11–15, 
17–21, 24–27, 29, 30, and 33), enteroviruses (serotypes 
68 and 69), and 3 HPeVs, while it efﬁ  ciently inhibited the 
infection of the NII561-2000 virus. These results suggest 
that the NII561-2000 agent is distinct from the examined 
known enteroviruses and HPeVs. 
We next examined the sensitivity of the virus to 5-
iodo-2′-deoxyuridine (IUDR) (14). The NII561-2000 virus, 
treated with 10–4.5 μmol/L IUDR, was injected into Vero 
cells. The IUDR treatment did not affect the CPE in Vero 
cells, indicating that the virus has the RNA genome (data 
not shown). We next examined the acid-stability and ther-
mostability of the NII561-2000 virus. The virus was treated 
at pH 3.0 for 3 h at room temperature, but the infectivity of 
the treated virus to Vero cells was little affected. Incuba-
tion of the virus at 50°C for 30 min reduced the infectivity, 
while incubation at 50°C for 1 h in the presence of 1 mol/L 
MgCl2 did not reduce the infectivity. These results indicate 
that the NII561-2000 virus has similar properties to human 
enteroviruses and HPeVs.
Genetic Analysis of NII561-2000
To determine the nucleotide sequence of the NII561-
2000 virus, the viral RNA was extracted from the puriﬁ  ed 
virus. The partial nucleotide sequences of cDNA clones 
derived from this viral RNA were determined. BLAST 
(www.ncbi.nlm.nih.gov/blast) search identiﬁ   ed that the 
nucleotide sequences of 2 isolated cDNAs showed high 
similarity with that of HPeV-2. By using these cDNAs as a 
starting material, the cDNAs containing the 5′ portion and 
3′ portion of the NII561-2000 gene were isolated by RT-
PCR with degenerated primers, 5′ RACE and 3′ RACE. 
The determined nucleotide sequence of NII561-2000 was 
7,347 nt in length, excluding a poly (A) tract. Following a 
709-nt 5′ UTR, a long open reading frame encoded a puta-
tive polyprotein precursor of 2,182 aa, which was followed 
by an 89-nt 3′ UTR. To verify the nucleotide sequence of 
the determined NII561-2000 genome, RT-PCR with a set 
of primers and RNA sample extracted from the virus-in-
fected Vero cells was carried out. The nucleotide sequences 
of the NII561-2000 genome obtained by using this RT-PCR 
method were perfectly matched with those of the originally 
determined sequences (data not shown).
Table 1. Neutralization activities of anti-HPeV antibodies using 
Vero cells* 
Virus
Antiserum
NII561-
2000 HPeV-1 HPeV-2 HPeV-3
NII561-2000 160 10 <10 <10
HPeV-1† <10 >1,280 <10 <10
HPeV-2 <10 <10 160 <10
HPeV-3 <10 <10 <10 >1,280
*HPeV, human parechovirus. 
†The HPeV strains used were Harris strain for HPeV-1, Williamson strain 
for HPeV-2, and A308/99 for HPeV-3. RESEARCH
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Phylogenetic tree analysis with complete P1 (VP0, 
VP3, and VP1) amino acid sequences showed that the 
NII561-2000 virus was most similar to HPeV-1/HPeV-2 
(Figure, panel A). The nucleotide sequence and amino acid 
similarities of NII561-2000 virus to HPeV-1 were 79.5% 
and 90.7%, those with HPeV-2 were 77.1% and 87.3%, 
those with HPeV-3 (A308/99) were 76.7% and 85.9%, 
those with HPeV-4 were 77.1% and 88.2%, and those with 
HPeV-5 (CT86-6760) were 77.0% and 86.9%, respectively 
(Table 2). Thus, the NII561-2000 virus is the most similar 
to HPeV-1 at the amino acid level. The VP1 capsid gene of 
NII561-2000 was the most divergent (33.8% at nucleotide 
level) from that of HPeV-5 (CT86-6760).
HPeVs have 9 polyprotein cleavage sites: VP0/VP3, 
VP3/VP1, VP1/2A, 2A/2B, 2B/2C, 2C/3A, 3A/3B, 3B/3C, 
and 3C/3D (Table 3). Comparison of these polyprotein 
cleavage sites among 6 HPeVs showed that those in VP3/
VP1, 2A/2B, 2B/2C, 2C/3A, 3A/3B, 3B/3C, and 3C/3D 
were conserved among all 6 HPeVs. The cleavage site in 
VP1/2A was identical among HPeV-1, HPeV-2, HPeV-4, 
HPeV-5, and NII561-2000 but not HPeV-3. The cleavage 
site in VP0/VP3 of NII561-2000 was identical to that of 
HPeV-3 but not to those of others.
The NII561-2000 virus, HPeV-1, HPeV-2, HPeV-4, 
and HPeV-5, but not HPeV-3, had an RGD (arginine-gly-
cine-aspartic acid) motif at the C terminus of VP1 (15). 
Figure. Phylogenetic tree analysis of the 
NII561-2000 virus and the NII561-2000–
related viruses. A) The phylogenetic tree of 
P1 amino acid sequences was constructed 
as described in Materials and Methods. 
Bar shows a genetic distance of 0.05. 
The following amino acid sequences were 
obtained from GenBank: L02971 for HPeV-
1 (Harris strain), AJ005695 for HPeV-2 
(Williamson strain), AB084913 for HPeV-3 
(A308/99), AJ889918 for HPeV-3 (Can82853-
01), DQ315670 for HPeV-4 (K251176-02), 
AM235750 for HPeV-4 (T75-4077), AF055846 
for HPeV-5 (CT86-6760), AM235749 for 
HPeV-5 (T92-15), and AF020541 for Ljungan 
virus (LV). B) Phylogenetic relationships 
among the NII561-2000 virus, the NII561-
2000–related viruses, and other prototype 
HPeVs based on comparisons of amino acid 
similarities of capsid protein (the ﬁ  rst 200 aa 
of VP0 sequences). The tree was constructed 
by the neighbor-joining method, using 
ClustalX. Bootstrap values are expressed 
in percentages after sampling 1,000×. Bar 
shows a genetic distance of 0.05.
Table 2. Comparisons of nucleotide and amino acid sequences among NII561-2000, HPeV-1, HPeV-2, HPeV-3, HPeV-4, 
and HPeV-5* 
% Nucleotide similarity (% amino acid similarity) with NII561-2000 
Sequence HPeV-1† HPeV-2 HPeV-3 HPeV-4 HPeV-5
5′UTR 85.3 87.3 86.9 88.5 86.9
VP0 73.6 (78.2)  76.0 (80.9)  70.6 (72.3)  72.6 (81.0)  73.1 (77.2) 
VP3 74.4 (84.7)  73.0 (80.2)  67.0 (74.1)  70.9 (78.0)  68.7 (73.1) 
VP1 71.7n(80.3)  67.3 (72.2)  71.1 (75.3)  70.0 (71.9)  66.2 (70.2) 
2A 80.8 (90.7)  77.1 (88.0)  81.0 (85.3)  77.3 (91.2)  76.2 (88.7) 
2B 78.6 (97.5)  77.8 (97.5)  82.0 (97.5)  79.8 (97.5)  78.7 (99.2) 
2C 84.7 (97.3)  76.4 (86.9)  79.2 (92.7)  78.7 (92.4)  79.2 (93.6) 
3A 85.7 (96.6)  77.4 (88.0)  78.0 (87.2)  75.5 (89.7)  78.6 (83.8) 
3B 81.4 (80.0)  72.9 (80.0)  73.3 (75.0)  66.7 (85.0)  70.0 (85.0) 
3C 84.2 (99.0)  82.7 (99.0)  82.3 (98.0)  82.5 (98.0)  80.5 (99.0) 
3D 83.2 (95.9)  83.7 (95.5)  83.9 (95.7)  84.2 (96.8)  87.2 (97.0) 
3′UTR 81.6 88.5 83.9 84.9 93.2
ORF 79.5 (90.7)  77.1 (87.3)  76.7 (85.9)  77.1 (88.2)  77.0 (86.9) 
*HPeV, human parechovirus; UTR, untranslated region; ORF, open reading frame. 
†The HPeV strains used were Harris strain for HPeV-1, Williamson strain for HPeV-2, A308/99 for HPeV-3, K2511876–02 for HPeV-4, and CT86–6760 
for HPeV-5. Novel Human Parechovirus
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The RGD motif may be used for an entry receptor of these 
HPeVs to attach, penetrate, or both, into host cells. Mu-
tant HPeV-1 viruses with 2 aa deletions in the RGD motif 
showed little infectivity, while an RGD-to-RGE (arginine-
glycine-glutamic acid) change showed reduced infectivity, 
and the resultant viruses possessed a rescued RGD. In addi-
tion, mutations at the +1 and +2 positions downstream from 
the RGD motif produced small virus–inducing plaques, and 
an M-to-P change at +1 position was lethal (15). The amino 
acids (+1 and +2 positions) downstream from the RGD mo-
tif of NII561-2000 were identical to those of HPeV-1.
The N terminal ends of VP4 of many picornaviruses are 
myristoylated, and they have a consensus myristoylation 
motif (16). HPeVs, including NII561-2000, lacked a my-
ristoylation motif in the corresponding VP0 sequence. My-
ristoylation of capsid proteins is suggested to play a role 
in virion assembly. Thus, the virion assembly mechanism 
of HPeVs, including NII561-2000, might be distinct from 
other picornaviruses, including poliovirus.
Isolation of HPeVs from Clinical Samples
By using cultured cells (Caco-2, RD-18S, Vero, 
HeLa, HEp-2, LLC-MK2, and BSC-1), we have isolated 
8,195 CPE-inducing agents from 13,656 clinical samples 
(stool, throat swab, and CSF) collected between 1991 and 
2005, at Niigata, Japan (Table 4, Table 5). The CPE mor-
phologic features and CPE-inducing cell types suggested 
that 1,521 isolates are likely to be enteroviruses, HPeVs, 
rhinoviruses, or other viruses, and the others are likely 
to be inﬂ  uenza viruses or adenoviruses. Neutralization 
tests that used antisera against enteroviruses and HPeV-1 
showed that 1,365 were enteroviruses and 12 were HPeV-
1, and the remaining 144 viruses were not neutralized 
by these agents. RT-PCR that used degenerate primers 
against HPeVs, enteroviruses, and rhinoviruses identiﬁ  ed 
29 HPeVs, 72 enteroviruses, and 26 rhinoviruses, respec-
tively. The remaining 17 viruses were not identiﬁ  ed by 
these methods. Thus, a total of 41 HPeVs were isolated 
from the samples collected in Niigata.
Phylogenetic tree analysis showed 14 HPeV-1, 16 
HPeV-3, and 1 HPeV-4, but no HPeV-2 and HPeV-5 
among the examined 41 HPeVs. In addition, 10 viruses, in-
cluding NII561-2000, formed a distinctive tree from those 
of the other HPeVs (Figure, panel B). Of note, in our search 
from 1991 through 2005, the NII561-2000–related viruses 
were isolated only in 2000 (3 cases) and 2001 (7 cases); 
HPeV-1 were isolated in 1991, 1998, 2001, 2004, and 
2005; HPeV-3 were isolated in 1998, 1999, 2000, 2001, 
2004, and 2005; and HPeV-4 was isolated only in 1993 
(Table 4). The clinical symptoms of the patients infected 
Table 3. Amino acid sequences of protein cleavage sites of HPeVs 
Virus VP0/VP3 VP3/VP1 VP1/2A 2A/2B 2B/2C 2C/3A 3A/3B 3B/3C 3C/3D
NII561-2000 N/G Q/N Q/S Q/G Q/G Q/T E/R Q/R Q/G
HPeV-1* N/A  Q/N Q/S  Q/G Q/G Q/T E/R  Q/R Q/G
HPeV-2 T/A  Q/N Q/S  Q/G Q/G Q/T E/R  Q/R Q/G
HPeV-3 N/G Q/N E/S  Q/G Q/G Q/T E/R  Q/R Q/G
HPeV-4 N/N Q/N Q/S  Q/G Q/G Q/T E/R  Q/R Q/G
HPeV-5 N/S  Q/N Q/S  Q/G Q/G Q/T E/R  Q/R Q/G
*The human parechovirus (HPeV) strains used were Harris strain for HPeV-1, Williamson strain for HPeV-2, A308/99 for HPeV-3, K2511876–02 for 
HPeV-4, and CT86–6760 for HPeV-5. 
Table 4. Numbers of isolated HPeVs in 1991–2005 at Niigata, Japan* 
HPeV subtype
Year Type 1 Type 3 Type 4 Type 6
No. isolated 
HPeVs
No. examined 
samples
No. isolated 
viruses
1991 1 00013 0 3 2 5 5
1992 0 00001 4 2 5 3
1993 0 01011 6 6 5 0
1994 0 00001 5 1 5 5
1995 0 00001 6 7 1 1 6
1996 0 00001 3 3 5 4
1997 0 00002 7 7 8 4
1998 1 1002 1 , 6 0 7 1 , 1 1 7
1999 0 3003 2 , 1 1 8 1 , 2 0 3
2000 2 2037 1 , 9 7 4 1 , 1 2 7
2001 4 5 0 7 16 1,699 989
2002 0 0000 2 , 7 8 3 1 , 7 8 7
2003 0 00009 8 6 5 9 7
2004 5 20075 8 4 3 2 9
2005 1 30045 6 6 3 7 9
Total 14 16 1 10 41 13,656 8,195
*HPeV, human parechovirus. RESEARCH
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with NII561-2000–related viruses were gastroenteritis, re-
spiratory symptoms, rash, and ﬂ  accid paralysis in addition 
to Reye syndrome (Table 5), and these disease categories 
were similar to those of other HPeVs (2,3).
Discussion
In this study, we isolated a novel HPeV (NII561-2000) 
from a 1-year-old girl with Reye syndrome and determined 
the nucleotide sequence. Nucleotide sequence analysis and 
mutual neutralization test indicated that the NII561-2000 
virus was distinct from 5 known HPeVs (Figure, panel A) 
(17). Thus, we propose that the NII561-2000 virus is the 
prototype of HPeV-6.
The NII561-2000 virus was originally isolated from a 
patient with Reye syndrome, an acute noninﬂ  ammatory en-
cephalopathy characterized by an antecedent viral infection, 
such as inﬂ  uenza or varicella (10–12). The signiﬁ  cance of 
the NII561-2000 virus in this syndrome is not clear, because 
our samples did not include any other samples from this pa-
tient. We also isolated 9 NII561-2000–related viruses from 
clinical samples collected from other patients. The clini-
cal  symptoms  of  the  persons  infected  with  NII561-2000–         
Table 5. Diseases associated with HPeVs isolated 1991–2005 in Niigata, Japan* 
Strain
HPeV
subtype Specimen Clinical symptom Sex Age, y Cell line(s)
NII1099-91 1 Stool Gastroenteritis F 1 BSC-1
NII1852-98 1 Throat swab Hand-foot-mouth disease M <1 CaCo2, RD-18S
NII2534-2000 1 Stool Fever of unknown origin M <1 CaCo2
NII2632-2000 1 Stool Gastroenteritis M 1 RD-18S, Vero
NII36-2001 1 Stool Gastroenteritis M 1 BSC-1
NII2647-2001 1 Throat swab Upper respiratory tract infection M 1 RD-18S
NII2715-2001 1 Stool Gastroenteritis M <1 CaCo2, RD-18S
NII2726-2001 1 Stool Gastroenteritis F 1 CaCo2
NII196-2004 1 Stool Gastroenteritis M 9 LLC-MK2
NII197-2004 1 Stool Gastroenteritis M <1 LLC-MK2
NII198-2004 1 Stool Gastroenteritis M <1 LLC-MK2
NII940-2004 1 Throat swab Bronchitis M <1 CaCo2, RD-18S, Vero
NII1056-2004 1 Stool Gastroenteritis F <1 LLC-MK2
NII751-2005 1 Stool Gastroenteritis M <1 CaCo2
NII7-98 3 Stool Gastroenteritis F 1 BSC-1
NII2486-99 3 Stool Rash F <1 Vero
NII2701-99 3 Throat swab Rash F 1 Vero
NII2927-99 3 Stool Aseptic meningitis M <1 Vero
NII2319-2000 3 Stool Upper respiratory tract infection M <1 BSC-1
NII2825-2000 3 Throat swab Upper respiratory tract infection M 1 Vero, LLC-MK2
NII2335-2001 3 Throat swab Rash F <1 Vero, LLC-MK2
NII2573-2001 3 Throat swab Rash F <1 Vero, LLC-MK2
NII2735-2001 3 Stool Aseptic meningitis F <1 Vero, LLC-MK2
NII2826-2001 3 Throat swab Upper respiratory tract infection M <1 Vero, LLC-MK2
NII2930-2001 3 Throat swab Myositis M 8 CaCo2, Vero
NII1018-2004 3 CSF Fever of unknown origin F <1 Vero, LLC-MK2
NII1063-2004 3 Stool Gastroenteritis M <1 CaCo2, LLC-MK2
NII414-2005 3 Throat swab Influenzalike illness M 4 Vero, LLC-MK2
NII562-2005 3 Throat swab Influenzalike illness F 35 LLC-MK2
NII572-2005 3 Throat swab Influenzalike illness M 5 Vero, LLC-MK2
NII370-93 4 Stool Lymphadenitis M 5 RD-18S, Vero, 
LLC-MK2
NII428-2000 6 Stool Gastroenteritis F 1 Vero
NII561-2000 6 CSF Reye syndrome F 1 Vero
NII2819-2000 6 Throat swab Rash M 2 BSC-1
NII2392-2001 6 Stool Flaccid paralysis M 1 CaCo2
NII2485-2001 6 Throat swab Upper respiratory tract infection F <1 RD-18S
NII2589-2001 6 Throat swab Gastroenteritis M 8 RD-18S
NII2611-2001 6 Stool Gastroenteritis F 3 CaCo2, Vero
NII2667-2001 6 Stool Gastroenteritis M 6 HeLa
NII2694-2001 6 Throat swab Rash M 2 CaCo2, RD-18S
NII2729-2001 6 Stool Gastroenteritis F 2 BSC-1
*HPeV, human parechovirus; CSF, cerebrospinal fluid. Novel Human Parechovirus
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related viruses were gastroenteritis, upper respiratory tract 
infection, rash, and ﬂ  accid paralysis. These disease catego-
ries of the NII561-2000–related virus are similar to those of 
other HPeVs, but the pathologic roles of the NII561-2000 
viruses in these diseases, including Reye syndrome, need 
further etiologic and biologic studies.
In our search at Niigata from 1991 through 2005, the 
NII561-2000 and related viruses were isolated only in 2 
consecutive years (2000 and 2001), HPeV-1 were isolated 
in 5 years, and HPeV-3 were isolated in 6 years. The ge-
netic variations of these NII561-2000–related viruses were 
small (Figure, panel B). These results suggest that a 2-year 
outbreak of NII561-2000–related virus may have occurred 
in Niigata, Japan.
Thirteen of 16 HPeV-3 isolated in Niigata were from 
the patients <3 years of age, consistent with the previous 
report (18). Sepsislike illness and central nervous system 
involvement were more frequently reported in children 
infected with HPeV-3 than HPeV-1 (18). Consistent with 
those ﬁ  ndings, the HPeV-3 infections in Niigata included 
2 aseptic meningitis patients, whereas no such illness was 
associated with HPeV-1.
HPeV-4 was isolated from a 5-year-old patient with 
lymphadenitis in Niigata (Table 5). Thus, this virus is prev-
alent and is likely to be pathogenic in at least 3 countries. 
The diseases associated with HPeV-4 in the Netherlands 
and the United States were fever and TORCH (toxoplasmo-
sis; other infections; namely, hepatitis B, syphilis, herpes 
zoster, rubella, cytomegalovirus, and herpes simplex virus 
infections) (6,19). Further analysis is required to establish 
an association of HPeV-4 with these diseases.
The degenerate primer set we used here was original-
ly developed by Ito et al. (5) to amplify 3 known HPeV 
cDNAs. Here, we successfully ampliﬁ  ed the NII561-2000 
viral cDNA and HPeV-4 from culture supernatants of the 
infected cells, indicating that this primer set can amplify 
the cDNA fragments of at least 5 HPeVs from culture su-
pernatants of infected cells. Thus, this primer set is a useful 
tool to determine the subtypes of HPeVs.
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